Multi-omics

business deal
#AI / data analytics / healthtech / informatics #Drug discovery #Mergers and acquisitions #Multi-omics

UCB to acquire IMIDomics’ Patient Insight Business  

Global pharmaceutical company UCB has acquired the Patient Insights Business of IMIDomics, giving it access to a large, multi-omics dataset for immunology studies.  IMIDomics’ Patient Insight Business includes over 18 years of clinical and molecular data generation. It integrates epidemiological information, clinical histories, imaging data, multi-omic profiles, and longitudinal patient samples.  … Read More

#News

#Drug discovery #Multi-omics #Multiomics #Nanopore sequencing #QA/QC

Guide: Sequencing solutions for more confident decision-making

Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started Guide from Oxford Nanopore Technologies, you will: Find out how Oxford Nanopore… Read More

#News

#Drug discovery #Multi-omics #Multiomics #Nanopore sequencing #QA/QC

Oxford Nanopore sequencing solutions for biopharma

Discover sequencing solutions that can be applied from biomarker discovery through to final product quality control (QC) testing, consolidating multiple legacy assays with one platform — and enabling faster, more confident decision-making. In this new getting started guide, you will: Find out how Oxford Nanopore sequencing delivers the multiomic insight… Read More

#Guides #Resources

Genomics
#Data #Drug discovery #Genomics #Multi-omics

Advancing drug discovery through multiomics  

John Lepore, MD, CEO of ProFound Therapeutics, explore how multiomics, combined with artificial intelligence and real-world data is advancing drug discovery. The drug discovery landscape is undergoing a transformative shift, driven by the growing demand for precision medicine and tremendous technological advances that inform systems biology. Traditional R&D approaches… Read More

#Exclusive Content

#Drug discovery #Multi-omics #Omics #Whitepaper

Accelerating pharma innovation with 5D multiomics – download now

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. A new Whitepaper from Element Biosciences discusses the AVITI24 5D multiomics… Read More

#News

#Drug discovery #Multi-omics #Omics #Whitepaper

Accelerating pharma innovation and drug discovery with 5D multiomics

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More

#Resources

Genomics concept
#AI / data analytics / healthtech / informatics #Drug discovery #eBook #Multi-omics

eBook: Omics-driven drug discovery

A new eBook is now available for download for free from DDW and Evotec. One of the givens of modern medicine is that a more profound understanding of the molecular complexity of disease processes will lead to more precise, personalised treatment options. Multiomics, integrating multiple types of data from… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #eBook #Multi-omics

Omics-driven drug discovery

One of the givens of modern medicine is that a more profound understanding of the molecular complexity of disease processes will lead to more precise, personalised treatment options. Multiomics, integrating multiple types of data from an individual participant’s biological sample, can provide a more holistic view of the molecular factors… Read More

#eBooks #Resources

#Drug discovery #Drug targets #Enhanced Genomics #Genomics #Multi-omics

Part 2: A day exploring Cambridge’s life science scene

DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with several local companies and attended events. The first of this series was a conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. Here, DDW summarises what was learnt about… Read More

#Exclusive Content

Neurons
#Alzheimer's #Collaboration #Enhanced Genomics #Genetics / genomics #Multi-omics #Neuroscience #University of Cambridge

Genomics partnership discovers novel targets for Alzheimer’s

Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.   Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.   The partnership… Read More

#News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Emulate #Gene expression #Gene therapy #Interview #Metabolomics #Multi-omics #Next generation sequencing #NGS #Omics #Organ-on-a-chip #Personalised medicine #Preclinical investigations #Spatial biology

Podcast: Cutting-edge tools shaping early-stage drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical… Read More

#News

Colorectal cancer
#Artificial intelligence (AI) #Cancer Research Horizons #Colorectal cancer #Multi-omics #Oncology

Partners develop AI tools to personalise colon cancer treatment

Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.  As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from… Read More

#Business & Investment #Cancer Research #News

#Drug discovery #High throughput screening #Multi-omics #Omics

Understanding the value of multi-omics

DDW’s Megan Thomas discusses the opportunity in the multi-omics sector by speaking with leading players and looking at the ways in which it can help us tackle disease. Importance of the multi-omics sector Multi-omics describes the crossover application of many high‐throughput screening technologies. These include genomics, transcriptomics, proteomics, metabolomics, epigenomics, glycomics,… Read More

#Exclusive Content